Acasti Pharma Inc. Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Note 14 - Capital and Other Components of Equity (Tables)

12 Months Ended

Mar. 31, 2019

	March 31, 2019				March 31, 2018				March 31, 2017				February 28, 2017 (Unaudited)
	Number outstanding		Amount		Number outstanding		Amount		Number outstanding		Amount		Number outstanding		Amount
			$				$				$				$
Liability
May 2018 Public offering Warrants 2018 (i)		10,188,100		8,246		-		-		-		-		-		-
Series December 2017 US Public offering Warrants 2017 (ii)		9,801,861		8,017		9,802,935		6,405		-		-		-		-
Series 8 Public offering Warrants December 2013 (iii)		-		-		18,400,000		21		18,400,000		209		18,400,000		187
		19,989,961		16,263		28,202,935		6,426		18,400,000		209		18,400,000		187
Equity
Public offering warrants
Public offering broker warrants May 2018 (iv)		547,975		283		-		-		-		-		-		-
Public offering U.S. broker warrants December 2017 (v)		495,050		406		495,050		406		-		-		-		-
Public offering warrants February 2017 (vi)		1,904,034		-		1,904,034		-		1,965,259		-		1,965,259		-
Private Placement- contingent warrants
2017 unsecured convertible debenture conversion option and contingent warrants (vii)		1,052,630		309		1,052,630		309		1,052,630		309		1,052,630		309
Series 9 Private Placement warrants 2013 (viii)		-		-		161,654		-		161,654		-		161,654		-
Series 2017 BW Broker warrants (ix)		-		-		-		-		234,992		144		234,992		144
		3,999,689		998		3,613,368		715		3,414,535		453		3,414,535		453